Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451630 | 0.89 | ST6GAL1 (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2113320 | 0.88 | LMNA (0.47) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6367031 | 0.87 | ST6GAL1 (0.37) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6361362 | 0.84 | L3MBTL1 (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5341103 | 0.84 | ST6GAL1 (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2522884 | 0.83 | SLC28A1 (0.41) | — | |
| SCHEMBL16243212 | 0.83 | SLC28A1 (0.41) | — | |
| SCHEMBL6363635 | 0.83 | ST6GAL1 (0.34) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6850447 | 0.79 | ST6GAL1 (0.32) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL7758241 | 0.79 | AHCY (0.51) | LMNATHRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090198047-A1 | 2'-Modified Oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20080032945-A1 | 2'-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007106907-A2 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070218490-A1 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-7138517-B2 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ISIS PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-6911540-B2 | 2′ Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-0942000-B1 | 2'-Modified oligonucleotides | ISIS PHARMACEUTICALS INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030187240-A1 | 2' -modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030036649-A1 | 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
| US-20030004325-A1 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6399754-B1 | CONTAINING SULFOPHOSPHATE GROUP | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-0497875-B1 | 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0942000-A2 | 2'Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218490-A1 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | POLRMT, RNGTT, POLM | LMNA 529/4885THRB 2012/4885MTOR 4711/4885 |
| US-20030036649-A1 | 2' modified oligonucleotides | DCLRE1B, POLRMT, POLM | LMNA 518/4885THRB 3199/4885MTOR 4884/4885 |
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ADAR, POLM, POLRMT | LMNA 357/4885THRB 2856/4885MTOR 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.